DIO2 functions via T3: an in vitro model for chondrogenesis  by Bömer, N. et al.
Figure 1. Heat map analysis of microarray data. Normal, OA and MCP-1 treated
sMPC mRNA was analyzed using microarrays. A heat map demonstrates that normal
and OA sMPCs display very distinct expression patterns, while normal sMPCs treated
with MCP-1 take on an expression proﬁle similar to OA sMPCs (A). Color range signiﬁes
either up regulation (red), down regulation (blue), no signiﬁcant difference (yellow) in
gene expression between samples).
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MONOCYTE CHEMOTACTIC PROTEIN-1 REGULATES THE
CHONDROGENIC ACTIVITY OF SYNOVIAL MESENCHYMAL
PROGENITOR CELLS
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Krawetz. Univ. of Calgary, Calgary, AB, Canada
Purpose: Osteoarthritis (OA) is a multifactorial, often progressive,
painful disease that often progresses with the apparently irreversible
loss of articular cartilage, exposing underlying bone, resulting in pain
and loss of mobility. This cartilage loss is thought to be permanent
due to ineffective repair, and apparent lack of stem/progenitor cells in
that tissue. However, the adjacent synovial lining and synovial ﬂuid
are abundant with mesenchymal progenitor/stem cells (sMPCs)
capable of differentiating into cartilage both in vitro and in vivo, but it
remains unknown if these cells play an active role in cartilage repair.
Previous studies have demonstrated that MPCs can home to factors
such as monocyte chemotactic protein 1 (MCP-1/CCL2) expressed
after injury. However, the role of MCP-1 in the recruitment and
retention of stem/progenitor cells to a site of injury or chronic disease
(such as OA) is not fully understood which makes the elucidation of
its roles in OA and stem cell biology in general particularly inter-
esting. In the current study, we present evidence suggesting that
MCP-1 is up regulated in the synovial ﬂuid of patients with OA and
exposure to this molecule triggers changes in sMPC transcriptional
regulation, leading to a loss of chondrogenic potential in this cell
population.
Methods: Knee synovial ﬂuid was aspirated from normal individuals
(n¼10) and patients with OA (n¼10). The inﬂammatory proﬁle of the
ﬂuid was analyzed using Luminex Multiplex Assays for 65 distinct
cytokines and chemokines. sMPCs were derived from fresh synovial
ﬂuid (normal and OA) by aspiration and centrifugation. After 7-14
days in culture, colonies were observed and the cells were sorted
using FACS for the CD105+, CD90+, CD73+, CD45-, CD11b-population.
Chondrogenesis of sMPCs was evaluated in each of the treatment
groups by quantifying the relative gene and protein expression of the
chondrogenic markers Sox9, Collagen2, and Aggrecan using quanti-
tative polymerase chain reaction (qPCR) and Western blot analysis.
Microarray analysis was performed using the Affymetrix GeneChip
Human Gene 1.0 ST and the data was examined using GeneSpring
software.
Results: MCP-1 is up-regulated in OA synovial ﬂuid compared to
normal samples and exposure to physiological (OA knee joint synovial
ﬂuid) levels of MCP-1 activates sMPCs (increasing telomerase activity),
while concurrently inhibiting these cells from undergoing chondro-
genesis (at the gene, protein, and primitive tissue levels). Furthermore,
exposure to physiological levels of MCP-1 triggers changes in the
transcriptome of sMPCs (Figure 1) and prolonged exposure to the
chemokine induces the expression of MCP-1 in sMPCs, resulting in
a positive feedback loop from which sMPCs cannot apparently escape
(Figure 2).
Conclusions: We have demonstrated that MCP-1 can signiﬁcantly
regulate the chondrogenic potential and telomerase activity of
human synovial MPCs possibly through modiﬁcation of the tran-
scriptional network within the cells. Understanding the mechanism
by which MCP-1 ‘re-programs’ these sMPCs may lead to novelFigure 2. Schematic diagram of the potential role of MCP-1 in endogenous cartilage rep
assistance from local sMPCs. After injury to the cartilage surface macrophages secrete fact
initiating chondrogenesis and effecting repair, while simultaneously increasing the prolifera
MCP-1 which ‘locks’ the joint in a viscous cycle of ineffective repair.pharmaceutical targets and interventions in OA possibly through
‘short circuiting’ the vicious cycle that appears to be activated by
this chemokine within the joint environment after the onset of
injury/OA.
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Purpose: Genetic studies of OA have provided new etiological clues
since many of the discovered gene products orchestrate the process
of skeletal morphogenesis. The gene product deiodinase type-2 (D2)
of the OA susceptibility gene DIO2 discovered by our group is
responsible for catalyzing the conversion of intracellular inactive
thyroid (T4) to active thyroid hormone (T3). This subsequently
signals the terminal maturation of the growth plate chondrocytes
leading to cell hypertrophy, breakdown and mineralization of the
cartilage and eventually formation of bone. Such an upregulation of
thyroid signaling in articular cartilage should be considered detri-
mental to the joint tissues. In this respect, functional genomic studies
indicated upregulation of DIO2 gene expression and protein in
cartilage obtained from OA-affected joints as compared to healthy
joints. This could be due to the assessed consistent allelic imbalanced
expression of the DIO2 risk allele observed in joint tissues. Further-
more, we showed that carrier status of the DIO2 susceptibility SNPs
interacts with the association between aspects of hip joint geometry
and OA susceptibility. In the current study, we aim to investigate the
role of aberrant DIO2 gene expression during endochondral ossiﬁ-
cation by interfering with D2 protein function in an in vitro chon-
drogenesis model.
Methods: The ‘RAAK’ study contains human bone marrow derived
mesenchymal stem cells (BM-MSCs) which were isolated from OA
affected hip joints of subjects undergoing total hip arthroplasty.
BM-MSCs of 5 subjects were cultured as micromasses and differ-
entiated into cartilage particles. These micromass cultures were
maintained up to 49 days. The role of D2 on chondrogenesis was
investigated by either enhancing (excess T3 or lentiviral induced
DIO2 over-expression) or inhibiting (Iodopanoic Acid or IOP) D2
function. The effect on chondrogenesis was examined by quantiﬁ-
cation of micromass sizes, and immunohistochemistry (IHC) of
matrix components and RT-qPCR of relevant genes at different time
points.
Results: We show that interference with the thyroid hormone pathway
by either lentiviral DIO2 over-expression or addition of excess T3 in
a human (BM-MSC) in vitro chondrogenesis model, has a signiﬁcant
detrimental effect on the endochondral ossiﬁcation process as reﬂected
by the marked reduction in the capacity to deposit cartilage ECM
components (Aggrecan and COL2; Figure 1, panel A,B and C,D), delayed
chondrogenesis/maturation (reﬂected by COL10; Figure 1, panel E,F)
and induced expression of the enzymatic degradation proteins
ADAMTS5 and MMP13 and mineralization (ALPL). Furthermore, these
detrimental effects could be brought about by DIO2 over-expression
alone. In contrast, adding an inhibitor of deiodinases (IOP) resulted in,
albeit more subtle, an elongation of the endochondral ossiﬁcation
process with slightly larger sized micromasses and higher levels of
GAGs, COL2 and COL10 for a longer period of time (up to 7 weeks). Also,
the structure of the matrix seems to be denser and better organized
with more cartilage like structures and inhibition of the terminal
maturation of chondrocytes towards bone as reﬂected by smaller
lacunae.
Conclusions: Together our data provide compelling insight in the
detrimental effect of DIO2 over-expression during endochondral
ossiﬁcation. Such insight helps to understand the underlying mecha-
nism by which the OA susceptibility gene DIO2 contributes to the
onset of OA. Our in vitro models are tailored to also explain underlying
mechanisms of other putative OA susceptibility genes such as GDF5
and DOTL1.Figure 1. Alcian Blue staining (A,B), Collagen type 2 IHC (C,D), and Collagen type 10
(E,F) with a 4x magniﬁcation (A,C, and E) and 20x magniﬁcation (B,D, and F) of the
RAAK-247 micromasses transduced with either an eGFP-control or lentiviruses
inducing overexpression of DIO2.
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Purpose: The pathogenesis of osteoarthritis (OA) is believed to involve
the actions of pro-inﬂammatory cytokines such as interleukin 1 (IL-1).
However, there are currently no disease-modifying OA drugs (DMOADs)
available to combat joint degeneration. Amajor limitation to developing
OA therapeutics is the availability of a high-throughput, patient-speciﬁc
screening system. Induced pluripotent stem cells (iPSCs) provide an
attractive cell source for this type of system, as they can be derived from
a skin biopsy and can be expanded indeﬁnitely in culture. Recent work
in our lab has demonstrated that cartilage engineered from iPSCs can
recapitulate many of the properties of native tissue. This approach can
provide virtually unlimited quantities of genetically deﬁned cartilage as
a model system of OA, facilitating the development of high-throughput
screening assays for DMOADs. The goal of this study was to examine the
inﬂuence of IL-1a on iPSC-derived cartilage as an in vitro model of OA
for drug screening.
Methods: A multistep differentiation and puriﬁcation protocol was used
to derive high quality engineered cartilage from murine iPSCs derived
from tail ﬁbroblasts. Cells were ﬁrst differentiated in micromasses using
